

IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
02126	JW THERAP-B	2020/10/28	2020/11/02	2020/11/03

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfs.com.hk or contact our account executives or customer service officers

Subscription Details via CASH Securities

Offer Period	2020/10/22-2020/10/28
Closing Time for Margin Application	2020/10/27 2:00pm
Subscription Fee	HKD 100
Indicative Interest Rate	0-2.98%
Days For Margin Financing	5 days
*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.	

JW (Cayman) Therapeutics Co. Ltd (2126.HK)

Share Offer Highlights

Total Number of Offer Shares:	97,692,000 Shares (subject to the Over-allotment Option)
- Number of Public Offer Shares:	9,770,000 Shares (subject to adjustment)
- Number of Placing Shares:	87,922,000 Shares (subject to adjustment and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 20.00- 23.80 per Share
2019 Historical P/E ratio:	-
Sponsor:	Goldman Sachs, UBS

Company Overview

The Company is a leading clinical and pre-clinical stage cell therapy company in China. Its vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. Relmacabtagene autoleucel ("relma-cel"), its lead product candidate, is an autologous anti-CD19 CAR-T therapy for relapsed or refractory ("r/r") B-cell lymphoma. In June 2020 the NMPA accepted for review our NDA relating to relma-cel as a third-line treatment for DLBCL, and in September 2020 the NMPA granted priority review status to our NDA relating to relma-cel. Moreover, in September 2020, the NMPA also granted Breakthrough Therapy Designation for relma-cel as a treatment for FL. The NMPA' s Breakthrough Therapy Designation process is designed to expedite the development and review of therapies that are intended for the treatment of serious diseases for which there is no existing treatment and where preliminary evidence indicates advantages of the therapy over available treatment options. Relma-cel is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China, and has potential to be a superior CAR-T therapy.

For the year ended December 31, 2018 and 2019 and the six months ended June 30, 2020, the Company's net losses were RMB272.6 mn, RMB633.3 mn and RMB650.0 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026

Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.